Navigation Links
Roper Industries Announces Record First Quarter Results

SARASOTA, Fla., April 26, 2011 /PRNewswire/ -- Roper Industries, Inc.  (NYSE: ROP) reported financial results for the first quarter ended March 31, 2011.

Diluted earnings per share were $0.91, as net earnings for the first quarter reached $89 million, a 49% increase over the first quarter of 2010.  Sales increased 21% to $645 million and orders increased 24% to an all-time record of $702 million.  

Operating income was $142 million, representing 22% of sales, an increase of 320 basis points over the prior year.  EBITDA reached $177 million and EBITDA margin expanded 310 basis points to a record 27.4% of sales.  

"Roper is off to a great start in 2011 with organic sales growth of 16% and orders that exceeded our expectations," said Brian Jellison, Roper's Chairman, President and CEO.  "We are encouraged by broad-based strength across all four of our segments, as each posted double-digit sales and orders growth.  As a result of strong operating leverage and exceptional execution by our businesses, we were able to expand both gross margin by 200 basis points and operating margin by 320 basis points in the quarter."

"With another solid quarter of cash generation, we reduced our outstanding debt by nearly $100 million, bringing net-debt-to-net capitalization to 25% and providing the Company with over $800 million in available liquidity.  Our acquisition pipeline is full and we see interesting opportunities for the remainder of the year," Mr. Jellison continued.

2011 Outlook and Guidance"We are well positioned for the balance of 2011 with a record backlog of $851 million and a first quarter book-to-bill ratio of 1.09," said Mr. Jellison.  

Roper is increasing its full year DEPS guidance to $3.97 - $4.12 from $3.82 - $4.02, and establishing second quarter DEPS guidance of $0.95 - $1.00.  The Company's guidance excludes future acquisitions. Table 1:  Sales GrowthQ1 2011Total Sales Growth

21%Acquisitions / Divestitures

4%Foreign Currency


16%Table 2:  EBITDA and EBITDA MarginQ1 2011Q1 2010Net Earnings

$89.0$59.7Add:  Interest Expense

16.716.2Add:  Income Taxes

37.025.3Add:  Depreciation & Amortization

34.328.5EBITDA (A)

$177.0$129.7Revenue (B)

$645.3$534.4EBITDA Margin (A)/(B)

27.4%24.3%Conference Call to be Held at 8:00 AM (ET) TodayA conference call to discuss these results has been scheduled for 8:00 AM ET on Tuesday, April 26, 2011.  The call can be accessed via webcast or by dialing +1 800-967-7134 (US/Canada) or +1 719-457-2639, using confirmation code 5338709.  Webcast information and conference call materials will be made available in the Investors section of Roper's website ( prior to the start of the call.  Telephonic replays will be available for up to two weeks by calling +1 (719) 457-0820 and using the access code 5338709.

About Roper IndustriesRoper Industries is a market-driven, diversified growth company and is a constituent of the S&P 500, Fortune 1000, and the Russell 1000 indices. Roper provides engineered products and solutions for global niche markets, including water, energy, radio frequency and research/medical applications.  Additional information about Roper Industries is available on the Company's website at

The information provided in this press release contains forward-looking statements within the meaning of the federal securities laws. These forward looking statements include, among others, statements regarding operating results, the success of our internal operating plans, and the prospects for newly acquired businesses to be integrated and contribute to future growth and profit expectations.  Forward looking statements may be indicated by words or phrases such as "anticipate," "estimate," "plans," "expects," "projects," "should," "will," "believes" or "intends" and similar words and phrases.  These statements reflect management's current beliefs and are not guarantees of future performance.  They involve risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement. Such risks and uncertainties include our ability to integrate our acquisitions and realize expected synergies.  We also face other general risks, including our ability to realize cost savings from our operating initiatives, general economic conditions, unfavorable changes in foreign exchange rates, difficulties associated with exports, risks associated with our international operations, difficulties in making and integrating acquisitions, risks associated with newly acquired businesses, increased product liability and insurance costs, increased warranty exposure, future competition, changes in the supply of, or price for, parts and components, environmental compliance costs and liabilities, risks and cost associated with asbestos related litigation and potential write-offs of our substantial intangible assets, and risks associated with obtaining governmental approvals and maintaining regulatory compliance for new and existing products.  Important risks may be discussed in current and subsequent filings with the SEC.  You should not place undue reliance on any forward-looking statements.  These statements speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.

Roper Industries, Inc. and SubsidiariesCondensed Consolidated Balance Sheets (unaudited)(Amounts in thousands)March 31,December 31,ASSETS20112010CURRENT ASSETS:  Cash and cash equivalents

270,394  Accounts receivable

413,371403,337  Inventories

198,788178,559  Unbilled receivable

79,07275,620  Deferred taxes

33,83432,894  Other current assets

43,12837,287Total current assets


103,639103,487OTHER ASSETS:  Goodwill

2,748,5102,727,780  Other intangible assets, net

1,083,4821,104,513  Deferred taxes

55,62957,850  Other assets

75,99477,803Total other assets

3,963,6153,967,946TOTAL ASSETS

$ 5,096,894$

37,778  Accrued liabilities

268,036298,080  Income taxes payable

--  Deferred taxes

10,66410,445  Current portion of long-term debt

81,82693,342Total current liabilities

507,541539,645NONCURRENT LIABILITIES:  Long-term debt

1,159,9611,247,703  Deferred taxes

474,185465,001  Other liabilities

73,07866,268Total liabilities

2,214,7652,318,617STOCKHOLDERS' EQUITY:  Common stock

977971  Additional paid-in capital

1,060,7851,045,286  Retained earnings

1,759,2821,680,849  Accumulated other comprehensive earnings

81,18843,978  Treasury stock

(20,103)(20,177)Total stockholders' equity


$ 5,096,894$
5,069,524Roper Industries, Inc. and SubsidiariesCondensed Consolidated Statements of Earnings (unaudited)(Amounts in thousands, except per share data)Three months endedMarch 31,20112010Net sales

$ 645,309$ 534,441Cost of sales

295,213254,876Gross profit

350,096279,565Selling, general and administrative expenses

208,096178,849Income from operations

142,000100,716Interest expense

16,69616,181Other income

711447Earnings from continuing operations before   income taxes

126,01584,982Income taxes

37,03625,257Net Earnings

$   88,979$   59,725Earnings per share:  Basic

.64  Diluted

.62Weighted average common and common  equivalent shares outstanding:Basic


98,15396,036Roper Industries, Inc. and SubsidiariesSelected Segment Financial Data (unaudited)(Amounts in thousands and percents of net sales)Three months ended March 31,20112010Amount%Amount%Net sales:  Industrial Technology

$ 169,982$ 135,312  Energy Systems & Controls

129,633105,678  Medical & Scientific Imaging

145,287130,244  RF Technology


$ 645,309$ 534,441Gross profit:  Industrial Technology

$   85,71450.4%$   67,51249.9%  Energy Systems & Controls

70,14654.1%53,49150.6%  Medical & Scientific Imaging

91,25462.8%77,51059.5%  RF Technology


$ 350,09654.3%$ 279,56552.3%Operating profit*:  Industrial Technology

$   46,18927.2%$   31,76623.5%  Energy Systems & Controls

29,04422.4%18,92317.9%  Medical & Scientific Imaging

35,03724.1%29,33422.5%  RF Technology


$ 155,22024.1%$ 112,22421.0%Net Orders:  Industrial Technology

$ 200,742$ 154,093  Energy Systems & Controls

134,205115,300  Medical & Scientific Imaging

150,265131,110  RF Technology


$ 702,299$ 567,246  *  Operating profit is before unallocated corporate general and administrative expenses.  These expenses were $13,220 and $11,508 for the three months ended March 31, 2011 and 2010, respectively.Roper Industries, Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows (unaudited)(Amounts in thousands)Three months endedMarch 31,20112010Net earnings

$  88,979$  59,725Non-cash items:Depreciation


25,05419,095Stock-based compensation expense

8,1127,008Income taxes

3,42411,353Changes in assets and liabilities:Receivables


(16,359)(2,344)Accounts payable

6,85412,901Accrued liabilities

(23,466)(24,762)Other, net

2,911(80)  Cash provided by operating activities

86,58495,086Business acquisitions, net of cash acquired

-(15,000)Capital expenditures

(8,813)(6,485)Other, net

(198)2,841  Cash used by investing activities

(9,011)(18,644)Principal debt borrowings

--Principal debt payments

(11,968)(2,999)Revolver borrowings (payments), net

(85,000)(40,000)Debt issuance costs


(10,458)(8,878)Excess tax benefit from share-based payment

2,8551,021Proceeds from exercise of stock options

8,6072,443Other, net

(118)366  Cash used by financing activities

(96,082)(48,047)Effect of exchange rate changes on cash

9,562(4,818)Net increase (decrease) in cash and equivalents

(8,947)23,577Cash and equivalents, beginning of period

270,394167,708Cash and equivalents, end of period


SOURCE Roper Industries, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Roper Industries Reschedules First Quarter 2011 Financial Results Conference Call
2. McDonald Hopkins Law Firm Alert: Recent Court of Appeals Decision Highlights the Need to Properly Define the Role of Sales Representatives
3. Software Development Firms New Intellectual Property Group, Blue Horseshoe IP Creates Solutions to Help Customers Optimize Supply Chain
4. ERT to Change Trading Symbol to "ERT" Effective March 7, 2011 to Properly Align Business Brand
5. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
6. 75 Percent of Hospital IT Leaders View Interoperability Between Vendor Systems as Critical to Operational Effectiveness in Healthcare Settings
7. Omnicell is First to Demonstrate Automated Dispensing Cabinet Interoperability at HIMSS11 Showcase
8. OnBase Proves Value of ECM Software in Achieving Interoperability in Healthcare
9. Recent Study Demonstrates Anti-Inflammatory Properties of Oligonol® Lychee Fruit Polyphenols in Humans
10. Effective Treatment of Lyme Disease-Related Arthritis Depends on Proper Diagnosis
11. Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase
Post Your Comments:
(Date:10/9/2015)... DIEGO , Oct. 9, 2015 Ansun ... (Infectious Disease Society of America ) regarding the compassionate ... transplant patient on a respirator who was co-infected with ... a five-day course of therapy, O 2 requirement ... the patient was able to go off the respirator ...
(Date:10/8/2015)... October 9, 2015 ® ... diagnostic colonoscopy. The NOCT study also assessed the ... --> ® ) in adult patients ... study also assessed the compliance, safety, patient acceptability ... today announced positive top line results for its ...
(Date:10/8/2015)... PITTSBURGH , Oct. 8, 2015 /PRNewswire/ ... pharmaceutical company, will host a conference call and webcast ... ET to review the value to be created for ... TASE) through Mylan,s offer to acquire the company. During ... outlines the compelling proposition for Perrigo shareholders. Mylan,s offer ...
Breaking Medicine Technology:
... IDEV Technologies, Inc. (IDEV) today announced the firm ... Australia,s regulatory agency for medical drugs and devices, for ... and peripheral procedures. "We are pleased to ... SUPERA VERITAS in the Australian market later this year," ...
... 28, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the ... Paris, France. "The data we are ... an important new treatment option for patients with multiple ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... Story Chaser is a ... by reading various classics and inspiring stories and as words drop down and users ... animations are extremely aesthetic and can be interacted with, making it a more engaging ...
(Date:10/9/2015)... ... 2015 , ... Doctors on Liens has teamed up with a ... needed medical care to personal injury victims. When personal injury victims suffer major, ... treat the variety of conditions ailing them. With the addition of this new ...
(Date:10/9/2015)... WASHINGTON, NH (PRWEB) , ... October 09, 2015 , ... ... Sore Throat Home Exam Aid, is now available online ( ) – just ... and Prevention (CDC) says officially begins in October. However, for many in the U.S., ...
(Date:10/9/2015)... ... October 09, 2015 , ... Head Over Heels Athletic Arts ... developmental camp at the Karolyi Ranch in Huntsville, Texas on October 17-21. , ... Heels girls team head coach and executive director, said. “It's a stepping stone into ...
(Date:10/9/2015)... ... October 09, 2015 , ... Cambias ... the surrounding communities, is initiating a combined charity effort with Animal Rescue New ... in southern Louisiana. , Animal Rescue New Orleans is a non-profit organization ...
Breaking Medicine News(10 mins):
... Eye Research Institute (SERI) found that increasing the contrast ... enjoyable to the visually impaired. // ,The U.S. ... device to help millions suffering eye diseases. People who ... from macular degeneration, diabetic retinopathy and other causes of ...
... family and community medicine and colleagues developed the latest tool ... developed a tool which is called the Newest vital sign. ... based on an ice cream nutrition label. Based on the ... literacy can be calculated. , Then it is ...
... has been legalized in Canada the sex workers feel that the ... public for negotiating with their customers in public and does not ... rented flat.// The sex workers organization feels that the law will ... to brutality and killing, as they are not sure about the ...
... undergo a liver transplant at the St James's University Hospital in ... to take as long as 10 hours, in which half the ... ,Lennox developed chronic liver problems and jaundice within weeks after his ... a transplant appeared to be the only way of saving his ...
... San Diego have designed mice containing fully functional human nerve ... neurodegenerative diseases such as Parkinson's and Alzheimer's. // ... the neurons were formed in the brains of mice that ... embryos. ,Studies showed that the human stem ...
... The human brain can be manipulated to get relief from ... University in California. ,As many as eight patients were ... brains while performing // mental exercises. Standard therapy has ... possibilities can be opened through the results of the research. ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: